Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
administered, agonist, aid, antagonist, Bavarian, burden, cardioversion, colon, disruption, domestic, eligible, EMANATE, ENHANZE, eventually, exploring, fluoropyrimidine, futile, Halozyme, Humana, humanitarian, IFM, immune, innate, intermediate, intravenously, irinotecan, large, lymph, mCRC, mm, modulate, negotiation, nominated, Nordic, NVAF, occurrence, ovarian, oxaliplatin, pathologic, population, prescribing, prostate, Prostvac, repaid, resident, restoration, restore, restoring, Rubraca, rucaparib, SCLC, step, STING, stomach, subcutaneously, successful, Supreme, technology, testing, Teva, topline, undergoing, USA
Removed:
brentuximab, cHL, Designation, extend, updated, vedotin
Filing tables
Filing exhibits
Related press release
Associated BMY transcripts
BMY similar filings
Filing view
External links